medwireNews : The EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion  for the first-line use of add-on olaparib in men with metastatic castration-resistant prostate cancer (CRPC).

The phase 1 RadioPARP trial points to the tolerability of administering olaparib concomitantly with adjuvant radiotherapy in patients with early-stage triple-negative breast cancer and residual disease after neoadjuvant chemotherapy.

Olaparib can be given alone or in combination with endocrine therapy.

Supplementing first-line abiraterone acetate with olaparib significantly improves the outcomes of patients with metastatic castration-resistant prostate cancer, show phase 3 data reported at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA.

Updated results from the OlympiA trial indicate that use of adjuvant olaparib significantly improves overall survival compared with placebo for patients with HER2-negative, early-stage breast cancer who have germline BRCA1/2 mutations.

Adding olaparib to durvalumab did not improve progression-free survival in the overall BAYOU trial population comprising unselected patients with metastatic urothelial carcinoma, but there was a signal of efficacy in the subgroup with homologous recombination repair gene mutations, say investigators. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Olaparib use is associated with reduced pain burden and better preservation of health-related quality of life relative to control treatments in men with metastatic castration-resistant prostate cancer harboring BRCA1 , BRCA2 , or ATM alterations, research shows.

Fred Saad provides an overview of the PROpel study of olaparib plus abiraterone acetate for the first-line treatment of metastatic castration-resistant prostate cancer, and outlines the next steps.

Judy Garber reports on the phase 3 OlympiA study suggesting that adjuvant olaparib could be an option for the treatment of patients with early-stage breast cancer and germline BRCA variants.

The benefit offered by olaparib in metastatic castration-resistant prostate cancer is attenuated when a more active standard of care is used as the comparator, suggests a network analysis of the PROfound and CARD trials.

The OlympiA study has demonstrated a significant reduction in the risk for recurrence and disease progression with adjuvant olaparib versus placebo in patients with HER2-negative, early-stage breast cancer and germline BRCA mutations.

ASCO 2021 video: Nadine Tung comments on the OlympiA study of the PARP inhibitor olaparib in the adjuvant early breast cancer treatment setting. 

medwireNews : Olaparib has been granted a positive opinion by the EMA for use in patients with metastatic castration-resistant prostate cancer (CRPC) with a somatic or germline BRCA1 or BRCA mutation.

The PROfound trial evaluated olaparib in metastatic castration-resistant prostate cancer ─ Maha Hussain discusses the clinical implications and practical applications of the findings (2:40).

The recommended olaparib dose  is 300 mg twice daily, given concurrently with gonadotrophin-releasing hormone therapy or bilateral orchiectomy.

Findings from the proof-of-principle Olaparib Expanded study indicate that patients with stage IV breast cancer and germline PALB2 or somatic BRCA1 / 2 mutations may benefit from olaparib treatment.

The addition of durvalumab and olaparib to neoadjuvant chemotherapy is associated with improved pathologic complete response in women with stage II or III HER2-negative breast cancer, show data from the I-SPY 2 trial.

A phase I/II trial has shown promising efficacy and tolerability for the combination of the PARP inhibitor olaparib with temozolomide in patients with previously treated small-cell lung cancer.

The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.

SOLO1 co-author Susana Banerjee provides a quick take on the study findings and discusses the challenges going forward (3:55).